TUMOR NECROSIS FACTOR (TNF) BLOCKER
Hyrimoz is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe rheumatoid arthritis. It is also indicated to treat juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease in adults, ulcerative colitis, and plaque psoriasis. Hyrimoz is also referred to by its drug name, adalimumab-adaz.
Hyrimoz is used as targeted therapy for rheumatoid arthritis. Hyrimoz is a member of a class of drugs called tumor necrosis factor (TNF) blockers. Hyrimoz is believed to work by blocking the activity of TNF, a substance that can cause inflammation and immune system diseases such as rheumatoid arthritis. Hyrimoz is biologically similar to the FDA-approved drug Humira (adalimumab).
How do I take it?
Prescribing information states that Hyrimoz is taken every other week.
Hyrimoz comes in the form of a subcutaneous injection.
The FDA-approved label for Hyrimoz lists common side effects including upper respiratory infections, headache, rash, and injection site reactions like redness, swelling, itching, and bruising.
Rare but serious side effects listed for Hyrimoz include serious infections, severe allergic reactions, cancer, low blood counts, demyelinating diseases (such as multiple sclerosis or Guillain-Barre syndrome), heart failure, and lupus-like syndrome.
For more details about this treatment, visit:
Hyrimoz — Sandoz